AUPP042397A0 - 5-arylpyrazole compounds - Google Patents

5-arylpyrazole compounds

Info

Publication number
AUPP042397A0
AUPP042397A0 AUPP0423A AUPP042397A AUPP042397A0 AU PP042397 A0 AUPP042397 A0 AU PP042397A0 AU PP0423 A AUPP0423 A AU PP0423A AU PP042397 A AUPP042397 A AU PP042397A AU PP042397 A0 AUPP042397 A0 AU PP042397A0
Authority
AU
Australia
Prior art keywords
arylpyrazole compounds
arylpyrazole
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPP0423A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Priority to AUPP0423A priority Critical patent/AUPP042397A0/en
Publication of AUPP042397A0 publication Critical patent/AUPP042397A0/en
Priority to JP52812799A priority patent/JP2002509554A/en
Priority to PCT/JP1998/005041 priority patent/WO1999025695A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
AUPP0423A 1997-11-18 1997-11-18 5-arylpyrazole compounds Abandoned AUPP042397A0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AUPP0423A AUPP042397A0 (en) 1997-11-18 1997-11-18 5-arylpyrazole compounds
JP52812799A JP2002509554A (en) 1997-11-18 1998-11-10 5-arylpyrazole compounds
PCT/JP1998/005041 WO1999025695A1 (en) 1997-11-18 1998-11-10 5-arylpyrazole compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP0423A AUPP042397A0 (en) 1997-11-18 1997-11-18 5-arylpyrazole compounds

Publications (1)

Publication Number Publication Date
AUPP042397A0 true AUPP042397A0 (en) 1997-12-11

Family

ID=3804703

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPP0423A Abandoned AUPP042397A0 (en) 1997-11-18 1997-11-18 5-arylpyrazole compounds

Country Status (3)

Country Link
JP (1) JP2002509554A (en)
AU (1) AUPP042397A0 (en)
WO (1) WO1999025695A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2493156A1 (en) * 2002-07-29 2004-02-05 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2004115436A (en) * 2002-09-26 2004-04-15 Nippon Nohyaku Co Ltd Method for producing pyrazole derivative
EP1603897A1 (en) * 2003-03-14 2005-12-14 Biolipox AB Pyrazole compounds useful in the treatment of inflammation
JP2008513427A (en) * 2004-09-20 2008-05-01 バイオリポックス エービー Pyrazole compounds useful for the treatment of inflammation
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
JP2009511560A (en) * 2005-10-13 2009-03-19 バイオリポックス エービー Naphthalene-disulfonamides useful for the treatment of inflammation
CN101558049B (en) * 2006-11-13 2012-08-15 诺瓦提斯公司 Substituted pyrazole and triazole compounds as KSP inhibitors
WO2008129276A1 (en) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides useful in the treatment of inflammation
GB0806744D0 (en) * 2008-04-14 2008-05-14 Syngenta Participations Ag Novel pyrazole derivatives
IL305573A (en) 2021-03-15 2023-10-01 Saul Yedgar HYALURONIC ACID-CONJUGATED DIPALMITOYL PHOSPHATIDYL ETHANOLAMINE IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) FOR TREATING OR ALLEVIATING INFLAMMATORY DISEASES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
DE4126543A1 (en) * 1991-08-10 1993-02-11 Chem & Pharm Patent Hold Ltd Drug compsn. contg. 3(5)-(hydroxyaryl)-pyrazole derivs. - for inhibition of lipoxygenase and cyclo:oxygenase in treatment of asthma, allergy, inflammation, skin disorders, myocardial infarction etc.
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
DE69430930T2 (en) * 1993-11-30 2003-02-20 Searle & Co Substituted pyrazolyl benzenesulfonamides for use in the treatment of inflammation
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
WO1999025695A1 (en) 1999-05-27
JP2002509554A (en) 2002-03-26

Similar Documents

Publication Publication Date Title
AU1709299A (en) Mixer-injectors
AU8921698A (en) Follistatin-3
AU9414098A (en) Ascorbyl-phosphoryl-cholesterol
AU7210598A (en) Novel compounds
AU6598798A (en) Resorcinyl-triazines
AU6804098A (en) Triazinylaminostilbene compounds
AU1027499A (en) 32P-polyphosphazene
AU9066598A (en) Substituted 4-benzoyl-pyrazoles
AU5272198A (en) EMP-charge-eliminator
AU7476598A (en) 18-substituted-19-nor-vitamin d compounds
AUPO941497A0 (en) Novel compounds
AU4117497A (en) Micropolarimeter
AU6998698A (en) Dioxacycloalkan-8-one
AUPP042397A0 (en) 5-arylpyrazole compounds
AU7124598A (en) Polymer-platinum compounds
AU6185898A (en) Clavaspirins
AU7761998A (en) Korrosionsschutzanstrichstoff
AU8214598A (en) 3-benzylpiperidine
AU8019998A (en) Fluoromethoximino compounds
AU6090898A (en) Substituted 4-benzoyl-pyrazoles
AUPO691897A0 (en) New compound
AU9753998A (en) Azaboroxine compounds
AU7041098A (en) Pi-complex compounds
AU9183798A (en) Catamaran - bicycle - kayak
AU5391798A (en) Thiamacrolides